ERBB2 and breast carcinoma: For those with HER2-positive breast cancer, the treatment typically includes monoclonal antibodies (Bighin et al., 2013), tyrosine kinase inhibitors (Deeks, 2017; Dhillon, 2019), and antibody-drug conjugates (Chung et al., 2020).